Clinical trial Recruiting at 1 site Observational Ages 18 and up

Analyzing tumor and blood samples to understand DNA changes in lung cancer patients

Official title: EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood

Run by University of California, Davis · NCT00899405 · Data updated 2026-11-12

This study looks at tumor and blood samples from lung cancer patients to see if certain DNA changes can help us understand their treatment outcomes better.

More Lung Cancer trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment800 (estimated)
SponsorUniversity of California, Davis
Academic / other
Locations1 site (Sacramento, California)
StatusRecruiting
StartedMay 19, 2004
Main results expectedMay 2034
Study endsMay 2034
Registry record updatedJune 25, 2026
Trial IDNCT00899405 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients with histologically or cytologically confirmed lung cancer.

Probably not a fit

Patients without a confirmed diagnosis of lung cancer or those who have not received prior EGFR inhibitors may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on analyzing tumor tissue and blood samples from patients diagnosed with lung cancer to investigate DNA changes, specifically looking at mutations in the EGFR pathway. By examining these samples, researchers aim to correlate the presence of EGFR mutations with clinical outcomes in patients. The study utilizes PCR techniques to detect these mutations, providing insights that may enhance understanding of lung cancer biology and treatment responses.

Why it matters

Potential benefit: If successful, this study could lead to improved identification of biomarkers that inform treatment decisions for lung cancer patients.

How similar studies have gone: Other studies examining DNA mutations in lung cancer have shown promising results, indicating that this approach is supported by prior research.

Who can join: the full rules

Show full inclusion / exclusion criteria
DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed lung cancer

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* May have received prior EGFR inhibitors

Where it's running

  • University of California Davis Cancer Center
    Sacramento, California, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.